After three years, The country will once again produce the Argentine Hemorrhagic Fever (FHA) vaccine that had been discontinued in 2018, after the underfunding of the National Institute of Human Viral Diseases (INEVH) “Dr. Julio Maiztegui ”from ANLIS Malbrán. Anmat has already approved the first batch of the vaccine, with a total of 7771 vials, equivalent to 77,710 doses.
The news was released this morning at a meeting attended by authorities from the institute and the Ministry of Health of the Nation. “The synergy that was generated between each of the actors, the public production, the ANLIS Malbrán institute, the support and trust generated by the support of the ANMAT, and the support of the Ministry of Health so that today, after years of divestment, we can once again have the vaccine ready to distribute ”, said the Minister of Health, Carla Vizzotti.
Vizzotti remarked that “production should never have been interrupted” of the vaccine.
For his part, the director of ANLIS said that the production of the vaccine is “something fundamental.” “With the support of the national government and the investment destined to carry out the remodeling of the production plant made it possible “, celebrated Pascual Fidelio.
“The Institute returns to giving answers to public health with an orphan vaccine, for a disease that claimed so many lives, as the only place of world production present in our vaccination calendar ”, highlighted the director of INEVH, María de los Ángeles Conti.
What is hemorrhagic fever
Is a serious viral disease spread through a wild rodent and mainly affects the provinces of Buenos Aires, Santa Fe, Córdoba and La Pampa.
INVEH is the sole producer of the FHA vaccine, Candid # 1, which was discontinued in October 2018.